Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma

Status Completed

Clinical Trial Summary

Primary Objective: - To determine the maximum tolerated dose (MTD) of Dasatinib in relapsed or refractory non-hodgkin's lymphoma (NHL) patients and to determine the safety of Dasatinib in NHL. Secondary Objectives: - To assess the complete and overall response rates for all Phase I and Phase II patients and to determine overall survival and event free survival for all Phase I and Phase II patients. - To assay the levels of kinase activity in NHL specimens and correlate this activity to patient outcomes.

Clinical Trial Description

Primary: - To determine the Maximum Tolerated Dose (MTD) of Dasatinib in relapsed or refractory Non-Hodgkin's lymphoma (NHL) patients and to determine the safety of Dasatinib in NHL Secondary Objective: - To assess the complete and overall response rates for all Phase I and Phase II patients and to assay the levels of kinase activity in NHL specimens and correlate this activity to patient outcomes. - To determine overall survival and event free survival for all Phase I and Phase II patients. Treatment Plan This study has two phases of treatment, Phase I and Phase II. The Phase I portion of the trial will consist of a dose escalation plan with 3-6 patients being enrolled into each dose cohort. The doses of Dasatinib used in Phase I are 100 mg, 150 mg, and 200 mg. The dose that is found to be tolerated the best and also has the best treatment results will be used for Phase II. An additional 29 patients will be enrolled into Phase II. All patients will receive Dasatinib in this study. Dasatinib will be administered orally (by mouth) once daily for 28 day cycles. A cycle will be considered 28 days. Dosing will be continuous with no interruptions, unless instructed to interrupt treatment by the treating physician. The patient will be restaged after every 2 cycles of therapy, every even cycle. Therapy may continue as long as there are no clinical signs of NHL progressing and the patient is tolerating the treatment with no side effects related to the therapy. If the patient is removed from study for any reason, he/she will be followed for survival until death. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00550615
Study type	Interventional
Source	University of Nebraska
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	September 17, 2007
Completion date	December 1, 2017

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03844048` - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial	Phase 3
Completed	`NCT01878890` - Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.	Phase 1
Completed	`NCT04152148` - A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients	Phase 1
Recruiting	`NCT05191225` - Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study	Phase 4
Recruiting	`NCT05096234` - 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma	Phase 2
Recruiting	`NCT05623982` - Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT03664635` - MB-CART20.1 Lymphoma	Phase 1/Phase 2
Recruiting	`NCT02356159` - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation	Phase 1/Phase 2
Terminated	`NCT01699581` - Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant	Phase 2
Completed	`NCT01763398` - Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study	N/A
Completed	`NCT01205503` - Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release	Phase 2
Completed	`NCT00975975` - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer	Phase 2
Completed	`NCT00969462` - Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma	Phase 4
Completed	`NCT00659425` - CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma	Phase 1
Completed	`NCT00608907` - An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)	Phase 1
Completed	`NCT00533728` - Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma	Phase 1
Withdrawn	`NCT00577161` - Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL	Phase 3
Terminated	`NCT00475332` - Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar	Phase 2
Completed	`NCT00430352` - MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.	Phase 4
Completed	`NCT00581646` - Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance	N/A